Targeting antioxidant vulnerabilities in KEAP1/NRF2 mutant NSCLC
针对 KEAP1/NRF2 突变 NSCLC 中的抗氧化脆弱性
基本信息
- 批准号:10902960
- 负责人:
- 金额:$ 24.89万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-01 至 2026-08-31
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
The transcription factor NRF2 is a central regulator of cellular redox balance. Mutations in NRF2 and its negative
regulator KEAP1 are found in 15-34% of non-small cell lung cancer (NSCLC). The result of these mutations is
constitutive NRF2 activation and chronic induction of a battery of NRF2 target genes, which confers resistance
to chemo/radiation therapy. While targeting NRF2 holds great therapeutic potential, there is no effective strategy
to inhibit the consequences of pathogenic KEAP1/NRF2 signaling. It is therefore critical to identify and
understand vulnerabilities of KEAP1/NRF2 mutant NSCLC to develop effective therapies for patients harboring
these mutations. NRF2 controls the transcription of many antioxidant enzymes, thereby regulating the
detoxification of reactive oxygen species. However, it remains largely unknown which specific antioxidant
enzymes can be therapeutically targeted to reverse the profound resistance of NRF2/KEAP1 mutations to
oxidative stress, the key mediator of chemo/radiation therapy. Glutathione (GSH)/GSH reductase (GSR) and
thioredoxin (TXN)/thioredoxin reductase (TXNRD) are two parallel, compensating thiol-dependent antioxidant
pathways that critically regulate and maintain cellular thiol redox homeostasis and protein dithiol/disulfide
balance. My preliminary results indicate that both GSR and TXNRD1 are strongly induced by NRF2 activation
and contribute to the intrinsic resistance to the pro-oxidant therapies. However, they play unique roles in different
cellular compartments. Specifically, NRF2 induced GSR acts to protect mitochondria from oxidation, while
TXNRD1 protects the cytosol. Further, TXNRD1 upregulation is associated with the suppression of other
selenoproteins, suggesting that NRF2 activation causes an imbalance in selenium distribution. Given the key
role of selenoprotein in redox biology, the switch in the production of the different selenoproteins induced by
NRF2 activation may create novel vulnerabilities of NRF2 active NSCLC with therapeutic potential. This proposal
is designed to further strengthen these observations by defining the mechanistic basis of how GSR contributes
to NRF2-mediated resistance to oxidative stress, and to leverage the imbalanced selenoprotein translation to
develop potent therapeutic strategies for KEAP1/NRF2 mutant NSCLC. The following specific aims are pursued
in this application: Aim 1. Investigate the role of GSR in NRF2-mediated resistance to oxidative stress. Aim 2.
Define the role of NRF2 as a modulator of the selenoproteome in NSCLC. The knowledge and scientific expertise
that I acquire from these proposed studies will facilitate my transition to an independent position. My long-term
goal is to study the antioxidant enzymes in cancer, with a major focus on selenoproteins. In addition to the
scientific goal, I have outlined a detailed career development plan to obtain skillsets that are key for leading a
research laboratory and establishing a strong research program. I will conduct the proposed research and carry
out the training plan under the guidance of my mentoring committee. I will embark on the excellent academic
environment provided by Moffitt Cancer Center to achieve these goals and transition to an independent position.
转录因子NRF 2是细胞氧化还原平衡的中心调节因子。NRF 2突变及其阴性
在15-34%的非小细胞肺癌(NSCLC)中发现了KEAP 1调节因子。这些突变的结果是
组成性NRF 2激活和一系列NRF 2靶基因的慢性诱导,这赋予了耐药性
化疗/放疗虽然靶向NRF 2具有巨大的治疗潜力,但没有有效的策略
抑制致病性KEAP 1/NRF 2信号传导的后果。因此,至关重要的是,
了解KEAP 1/NRF 2突变型NSCLC的脆弱性,为携带KEAP 1/NRF 2突变型NSCLC的患者开发有效的治疗方法。
这些突变。NRF 2控制许多抗氧化酶的转录,从而调节抗氧化酶的活性。
活性氧的解毒。然而,在很大程度上仍然不清楚哪种特定的抗氧化剂
酶可以在治疗上靶向逆转NRF 2/KEAP 1突变对
氧化应激,化疗/放疗的关键介质。谷胱甘肽(GSH)/GSH还原酶(GSR)和
硫氧还蛋白(TXN)/硫氧还蛋白还原酶(TXNRD)是两种平行的、补偿性的巯基依赖性抗氧化剂
关键调节和维持细胞巯基氧化还原稳态和蛋白质二巯基/二硫化物的途径
平衡我的初步结果表明,GSR和TXNRD 1都是由NRF 2激活强烈诱导的
并有助于对促氧化剂疗法的内在抗性。然而,它们在不同的领域发挥着独特的作用。
细胞间室具体而言,NRF 2诱导的GSR起到保护线粒体免受氧化的作用,而
TXNRD 1保护细胞质。此外,TXNRD 1的上调与其他免疫抑制有关。
硒蛋白,表明NRF 2激活导致硒分布的不平衡。鉴于钥匙
硒蛋白在氧化还原生物学中的作用,
NRF 2激活可能会产生具有治疗潜力的NRF 2活性NSCLC的新漏洞。这项建议
旨在通过定义GSR如何贡献的机制基础来进一步加强这些观察
NRF 2介导的抗氧化应激,并利用不平衡的硒蛋白翻译,
为KEAP 1/NRF 2突变型NSCLC开发有效的治疗策略。具体目标如下:
在本申请中:目标1。研究GSR在NRF 2介导的抗氧化应激中的作用。目标二。
确定NRF 2作为非小细胞肺癌硒蛋白质组调节剂的作用。知识和科学专长
我从这些拟议的研究中获得的知识将有助于我过渡到一个独立的职位。我的长期
目标是研究癌症中的抗氧化酶,主要关注硒蛋白。除了有
科学的目标,我已经概述了一个详细的职业发展计划,以获得技能,这是领导一个
研究实验室和建立强大的研究计划。我将进行拟议的研究,
在我的指导委员会的指导下制定培训计划。我将走上优秀的学术
莫菲特癌症中心提供的环境,以实现这些目标,并过渡到独立的立场。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Chang JIANG其他文献
Chang JIANG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Chang JIANG', 18)}}的其他基金
Targeting antioxidant vulnerabilities in KEAP1/NRF2 mutant NSCLC
针对 KEAP1/NRF2 突变 NSCLC 中的抗氧化脆弱性
- 批准号:
10428798 - 财政年份:2022
- 资助金额:
$ 24.89万 - 项目类别:
相似海外基金
Analysis of the antioxidant function of xCT in lymphatic endothelial cells and its significance in oral squamous cell carcinoma.
淋巴管内皮细胞xCT抗氧化功能分析及其在口腔鳞癌中的意义
- 批准号:
23K16139 - 财政年份:2023
- 资助金额:
$ 24.89万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Transcriptional Activation of p62 by the master antioxidant NRF2 in EBV latency
EBV潜伏期主要抗氧化剂NRF2对p62的转录激活
- 批准号:
10726975 - 财政年份:2023
- 资助金额:
$ 24.89万 - 项目类别:
Mitochondria-targeted antioxidant supplementation for improving age-related vascular dysfunction in older adults: the role of circulating factors
线粒体靶向抗氧化剂补充剂可改善老年人与年龄相关的血管功能障碍:循环因子的作用
- 批准号:
10606926 - 财政年份:2023
- 资助金额:
$ 24.89万 - 项目类别:
NAD(P)H quinone oxidoreductase 1 (NQO1)-mediated bypass of mitochondrial electron transport chain with artificial and endogenous substrates
NAD(P)H 醌氧化还原酶 1 (NQO1) 介导的人工和内源底物线粒体电子传递链旁路
- 批准号:
10789749 - 财政年份:2023
- 资助金额:
$ 24.89万 - 项目类别:
Biology the initiator: Harnessing Reactive Oxygen Species for Biocompatible Polymerization
生物学引发者:利用活性氧进行生物相容性聚合
- 批准号:
10667740 - 财政年份:2023
- 资助金额:
$ 24.89万 - 项目类别:
CAREER: Oligomeric Stoichiometry of Superoxide Dismutase 1 and Neuronal Antioxidant Defense
职业:超氧化物歧化酶 1 的寡聚化学计量和神经元抗氧化防御
- 批准号:
2237129 - 财政年份:2023
- 资助金额:
$ 24.89万 - 项目类别:
Continuing Grant
Development of a new class of BLVRB-targeted redox therapeutics in breast cancer
开发一类新型 BLVRB 靶向乳腺癌氧化还原疗法
- 批准号:
10759653 - 财政年份:2023
- 资助金额:
$ 24.89万 - 项目类别:
Racial disparities of open angle glaucoma: A study of mitochondria and oxidative stress in human trabecular meshwork
开角型青光眼的种族差异:人类小梁网线粒体和氧化应激的研究
- 批准号:
10735655 - 财政年份:2023
- 资助金额:
$ 24.89万 - 项目类别:
Impact of obesity on chemotherapy-induced muscle mitochondrial dysfunction
肥胖对化疗引起的肌肉线粒体功能障碍的影响
- 批准号:
10752436 - 财政年份:2023
- 资助金额:
$ 24.89万 - 项目类别: